Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 17;21(12):4309.
doi: 10.3390/ijms21124309.

Current Perspectives on 89Zr-PET Imaging

Joon-Kee Yoon  1 , Bok-Nam Park  1 , Eun-Kyoung Ryu  2 , Young-Sil An  1 , Su-Jin Lee  1
Affiliations
Review

Current Perspectives on 89Zr-PET Imaging

Joon-Kee Yoon et al. Int J Mol Sci. .

Abstract

89Zr is an emerging radionuclide that plays an essential role in immuno-positron emission tomography (PET) imaging. The long half-life of 89Zr (t1/2 = 3.3 days) is favorable for evaluating the in vivo distribution of monoclonal antibodies. Thus, the use of 89Zr is promising for monitoring antibody-based cancer therapies. Immuno-PET combines the sensitivity of PET with the specificity of antibodies. A number of studies have been conducted to investigate the feasibility of 89Zr immuno-PET imaging for predicting the efficacy of radioimmunotherapy and antibody therapies, imaging target expression, detecting target-expressing tumors, and the monitoring of anti-cancer chemotherapies. In this review, we summarize the current status of PET imaging using 89Zr in both preclinical and clinical studies by highlighting the use of immuno-PET for the targets of high clinical relevance. We also present 89Zr-PET applications other than immuno-PET, such as nanoparticle imaging and cell tracking. Finally, we discuss the limitations and the ongoing research being performed to overcome the remaining hurdles.

Keywords: 89Zr; monoclonal antibody; oncological imaging; positron emission tomography.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Radioactive decay scheme for 89Zr (A) and 124I (B).
Figure 2
Figure 2
Scheme of the bioconjugation and radiolabeling of 89Zr-desferrioxamine B (DFO)-J591. This is adapted from Zeglis, B. M., Lewis, J. S. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. J. Vis. Exp. 2015, 96, e52521, doi:10.3791/52521.
See this image and copyright information in PMC

References

    1. Hustinx R., Benard F., Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin. Nucl. Med. 2002;32:35–46. doi: 10.1053/snuc.2002.29272. - DOI - PubMed
    1. Sharma P., Kumar R., Alavi A. PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy. PET Clin. 2015;10:495–505. doi: 10.1016/j.cpet.2015.05.007. - DOI - PubMed
    1. Zhou Y., Baidoo K.E., Brechbiel M.W. Mapping biological behaviors by application of longer-lived positron emitting radionuclides. Adv. Drug Deliv. Rev. 2013;65:1098–1111. doi: 10.1016/j.addr.2012.10.012. - DOI - PMC - PubMed
    1. Kairemo K.J. Positron emission tomography of monoclonal antibodies. Acta Oncol. 1993;32:825–830. doi: 10.3109/02841869309096142. - DOI - PubMed
    1. Link J.M., Krohn K.A., Eary J.F., Kishore R., Lewellen T.K., Johnson M.W., Badger C.C., Richter K.Y., Nelp W.B. Zr-89 for antibody labeling and positron emission tomography. J. Label. Compd. Radiopharm. 1986;23:1297–1298.

LinkOut - more resources